FDA Seeks Additional Comment on Gene/Cell Therapy Guidance

Drug Industry Daily
A A
The wrangling over trial design guidance for gene/cell therapies will extend into next year as the FDA tries to satisfy industry concerns about how elements of the trials can be standardized.

To View This Article:

Login

Subscribe To Drug Industry Daily